

Study of Incidence, Clinical Profile and Electrophysiological Patterns in Each Type of Diabetic Neuropathy and the Extent of Their Clinical Correlation.

Neeraj.E¹ Prof.Sivakumar.S² Prof.Thiruvartchelvan.K³

¹ (Assistant Professor, Department of Neurology, Govt Salem Medical College, Dr.MGR Medical University, India)

²(Professor, Department of Neurology, Govt Salem Medical College, Dr.MGR Medical University, India)

³ (Professor, Department of Neurology, Govt Salem Medical College, Dr.MGR Medical University, India)

Corresponding Author: Neeraj.E

Abstract:

Aims and objectives: To assess the incidence , clinical profile of each type of Diabetic Neuropathy. To study the electrophysiologic patterns in each type of Diabetic Neuropathy and the extent of their clinical correlation.

Methodology: This study was done over a period of 9 months - between August 2018 to April 2019 as a cross sectional study. 148 patients were selected for study, out of the 196 patients screened. Nerve conduction study were conducted for those diabetic patients with symptoms of peripheral neuropathy with our standard RMS machine. **Results:** Demographic, clinical phenomenology and electrophysiological properties of various types of diabetic peripheral neuropathy were assessed and correlated accordingly.

Date of Submission: 09-05-2019

Date of acceptance: 25-05-2019

I. Introduction

Peripheral neuropathy caused by Diabetes (DM) was recognised only in 1864 by Marchel de Calvi⁽¹⁾ Till then it was assumed that diabetes was caused by disease of the nervous system. However, once the relationship was rightly recognised, much documentary evidence soon emerged regarding the various clinical manifestations occurring in diabetic peripheral neuropathy. Thus, the loss of tendon reflexes in the legs was described by Bouchard (1887),⁽²⁾ similarities to tabes stressed by Althaus (1885) ⁽³⁾, spontaneous pain and hyperesthesia by Pavy (1885)(1904) ⁽⁶⁾ and motor manifestations by Bruns (1890) ⁽⁶⁾ and Charcot (1890) and cranial nerve involvement by Ogle (1896). ⁽⁸⁾ While Leyden (1893) ⁽⁹⁾ and Pryce (1893) ⁽¹⁰⁾ set out a classification of the different manifestations of the disease, it was Rundles who in 1945 first drew attention to the autonomic nerve involvement in diabetes. Later, scientists turned their interest to the etiopathogenetic mechanisms resulting in peripheral neuropathy. This in turn gave impetus to the experimental production of diabetic neuropathy (DN) in order to understand the evolution of the disease. Though a large volume of work has been carried out in this regard and many problems solved, many questions still remain unanswered. There is a need, therefore, for more comprehensive studies of the prevalence, severity, natural history, and cause of specific types of diabetic neuropathy.

II. Aims And Objectives

1. To assess the incidence of various types of Diabetic Neuropathies
2. To examine the Clinical Profile of each type of Diabetic Neuropathy
3. To study the Electrophysiologic patterns in each type of Diabetic Neuropathy and the extent of their clinical correlation.

III. Materials And Methods

Inclusion criteria

1. Diabetic patients referred to Neurology O.P.D for symptoms of peripheral neuropathy were assessed and those with clinically demonstrable Peripheral Neuropathy(DPN) were screened.
2. Patients who were admitted in General Medical and Neurology ward with symptoms related to diabetic neuropathy were also selected for this study.

Exclusion Criteria:

1. Patients with a family history of inherited neuropathies, occupational or environmental history of heavy metal exposure, history of lumbar or cervical radiculopathy as well as patients using medications which could cause polyneuropathy were excluded.
2. Patients with nutritional deficiencies, collagen vascular disease, malignancies, tabes dorsalis, toxin exposure (e.g., alcohol, occupational toxins, vitamin B6, and medications known to be associated with peripheral neuropathy), hypothyroidism, pernicious anemia, dysproteinemias, amyloidosis, AIDS, spinal cord disease, and cauda-equina syndrome were excluded.

IV. Methodology

This study was done over a period of 9 months - between August 2018 to April 2019 .About 148 patients were selected for study, out of the 196 patients screened. The study protocol was approved by the Ethics Committee and all subjects gave their informed consent prior to the study.

Assessment of neuropathy: Determination of whether a patient had neuropathy was based on review of the medical record, neurologic tests including bedside autonomic function tests, nerve conduction (NC) abnormalities.

Three approaches were used to determine whether a neurologic abnormality was due to diabetes mellitus or to another cause: (1) the patient's history and the medical record were searched (2) additional tests were performed if needed; and (3) judgments were made as to whether the findings were typical of diabetic neuropathy.

Systematic questioning, including family history of nondiabetic peripheral nerve disease and the presence of toxic, metabolic, mechanical, and vascular causes of nerve disease, was conducted. All patients underwent tests for complete blood count and routine serum chemistry including lipid profiles as well as tests for thyroid hormones, and E.C.G.

Standardization of examining methods.

History and physical examination were included. In the sensory examination ambiguous findings were considered negative. The response to each test were considered normal, decreased, or absent. The instruments used were **1)** a disposable pin for pain evaluation, **2)** a cotton tip for light touch, **3)** a 128 Hz tuning fork for vibration sensation, and **4)** finger and toe movements with immobilization of the proximal joint to evaluate joint position. The sites examined included the distal toe and distal finger. The motor system was examined manually for individual muscles with a previously used validated grading system.. Muscle testing is of limited value in assessing mild diabetic neuropathy. Weakness appears late and usually only involves intrinsic foot muscles and ankle dorsiflexors; more proximal muscles are only involved in more severe cases of diabetic polyneuropathy. Reflexes were classified as **1)** present and active, **2)** present and hypoactive, and **3)** absent. Autonomic function tests were done for symptomatic patients.

Electrodiagnostic Measures-Standardization

The RMS system was used. Recommended filter settings (approximate values) were 20-3,000 Hz bandpass for sensory studies, 2-10,000 Hz bandpass for motor studies, and 20-10,000 Hz bandpass for needle electromyography.

Protocol for electrodiagnostic test

A) Motor nerve conduction studies

1. Unilateral studies of ulnar and median nerve including F waves in the upper limb
2. Unilateral studies of peroneal and posterior tibial nerve including F wave in the lower limb
3. Measurement of muscle action potential amplitude and latency at each site of stimulation and calculation of segmental conduction velocity

B) Sensory nerve conduction studies

1. Unilateral studies of ulnar and median nerve in the upper limb
2. Unilateral studies of either sural or medial plantar nerve in the lower limb
3. Measurement of nerve action potential amplitude and latency at each site of stimulation and calculation of segmental conduction velocity

C) Studies of additional nerves were undertaken to characterize abnormalities based on the distribution of clinical symptoms or signs.

D) Facial nerve conduction was done in all patients (even those without clinical involvement)

E) The normal values for representative nerve conduction values at various sites of stimulation were derived at after analyzing the NC of 30 age matched patients who came to Neurology OPD for complaints other than neuropathy.

Motor Nerve Conduction

| Nerve | Distal Latency (ms) | Amplitude (mv) | CV (m/s) | F-Wave Latency (ms) |
|----------|---------------------|----------------|----------|---------------------|
| Median | <4.2 | >4 | >49 | <31 |
| Ulnar | <3.4 | >6 | >49 | <32 |
| Tibial | <6.0 | >3.5 | <40 | <56 |
| Peroneal | <6.0 | >2.2 | <40 | <56 |
| Facial | <1.1 | >1.4 | - | - |

Sensory Nerve Conduction

| Nerve | Amplitude (uV) | CV (m/s) |
|--------|----------------|----------|
| Median | >18 | - |
| Ulnar | >16 | - |
| Sural | >6 | >40 |

Sympathetic skin Response (SSR) and Heart rate variability(R-R interval ratio) has also been done for all patients under the study using the same NCS machine.

V. Results

Clinical Characteristics of Study Subjects

The mean age of the diabetics was 54.0 ± 12.4 years. Their ages ranged from 30–68years. The duration of diabetes varied from newly detected to more than 20 years with a mean duration of 8.0 ± 6.9 years. Of the 148 patients 88 were males (59.4%) and 60 females (41.6%).

The highest proportion among the diabetics was in the age group of 50–59 years with a frequency of 35.2%.

| Characteristics | Diabetics (N=148) |
|---------------------------------------|-------------------|
| Number (male/female) | 88/60 |
| Age (years) (mean, SD) | 53.0 ± 12.4 |
| Duration of diabetes mellitus (years) | 8.4 ± 6.9 |

Most of the patients were type II, (88.2%) while 16 were type I (10.8%). The mean duration of DM was 8.4 ± 6.9 years. Oral hypoglycemic agents (OHG) were the treatment used by 81 patients (59.6%), followed by insulin 46 (33.8%), diet 5 (3.7%) and combined OHG and insulin in 4 (2.9%). Poor glycemic control was found in 87 patients (64%) while 49 (36%) were well controlled.

Eighty-nine (57.3%) patients were hypertensive while hyperlipidemia was found in 48 (30.7%) and a history of smoking in 43 (27.3%). Normal NCS were found in 26 patients (18%).

Abnormal NCS were found in 122 patients (80%). Nerve conduction abnormalities in symptomatic patients were significantly related to poor glycemic control. Seventy-one (81.6%) poorly controlled patients had abnormal NCS as compared to 16 (18.4%) well controlled patients (P <0.001). Long duration of DM was also strongly related to abnormalities in NCS, the mean duration of DM in patients with NCS abnormalities was 7.4 years as compared to 3.1 years in those with normal NCS (P <0.001). Abnormal NCS were also significantly associated with insulin use, 32 (69.6%) of those on insulin showed abnormal NCS compared to 14 (30.4%) who showed normal NCS.

There was no significant relation between abnormal NCS and patients age (p0.4), sex (p0.7), type of DM (p 0.1), hypertension (p 0.5), hyperlipidemia (p0.23) or smoking (p0.13)

SEX DISTRIBUTION

A total of 148 patients fulfilled the criteria were included in the study. There were 88(59%) males and 60(41%) females among 148 diabetic patients.

Table 1: Sex Distribution

| | |
|----------------------|---------|
| TOTAL NO.OF PATIENTS | 148 |
| MALES | 88(59%) |
| FEMALES | 60(41%) |

AGE AND SEX DISTRIBUTION:

Males predominated in all age groups. Around two thirds of males (85%) were in the age group between 40 and 70 years and two-third of females (84%) were in the age group between 40 and 70 years. The Table 2 shows age distribution based on sex.

Table 2 : Age and Sex Distribution

| | MALES | FEMALES |
|----------------|---------|---------|
| 30 TO 40 YEARS | 13(15%) | 9(16%) |
| 40 TO 50 YEARS | 23(26%) | 11(19%) |
| 50 TO 60 YEARS | 27(30%) | 23(37%) |
| 60 TO 70 YEARS | 25(28%) | 17(28%) |

DURATION OF DIABETES

Among the study population, patients with duration of diabetes more than 5 years was 88(56% of male and 57% of female patients)

Table 3 : Duration of Diabetes

| | MALES | FEMALES |
|--------------|---------|---------|
| 2 TO 3 YEARS | 14(15%) | 7(13%) |
| 3 TO 4 YEARS | 11(13%) | 7(13%) |
| 4 TO 5 YEARS | 11(13%) | 10(19%) |
| 5 TO 6 YEARS | 24(26%) | 18(28%) |
| 6 TO 7 YEARS | 12(13%) | 10(16%) |
| >7 YEARS | 16(17%) | 8(13%) |

DURATION OF SYMPTOMS

Among the patients studied about two thirds (78% of males and 57% females) had diabetic neuropathic symptoms in the duration of 6 months to more than 2 years as shown in table 4.

Table 4 : Duration of Symptoms

| | MALES | FEMALES |
|----------------|---------|---------|
| <3MONTHS | 4(4%) | 1(1%) |
| 3 TO 6 MONTHS | 9(11%) | 5(9%) |
| 6 TO 12 MONTHS | 12(14%) | 13(22%) |
| 1 TO 2 YEARS | 21(24%) | 13(22%) |
| >2 YEARS | 42(47%) | 28(45%) |

| CLINICAL SYMPTOMS | MALE | FEMALE | TOTAL |
|-----------------------------|---------|---------|----------|
| Numbness of hands and feet | 63(63%) | 46(72%) | 109(70%) |
| Pins and needles sensations | 33(36%) | 42(66%) | 86(55%) |
| Burning feet | 26(28%) | 18(28%) | 44(28%) |
| Unsteadiness in darkness | 42(46%) | 34(53%) | 76(49%) |

| WEAKNESS | PROXIMAL | DISTAL |
|----------------------------|----------|--------|
| UPPER LIMB | 3 | 36 |
| LOWER LIMB | 6 | 28 |
| BOTH UPPER AND LOWER LIMBS | 3 | 31 |

| AUTONOMIC FUNCTIONS ABNORMALITY | |
|---|---------|
| SWEATING DISTURBANCES AND TROPHIC CHANGES | 13(8%) |
| BP AND HEART RATE RESPONSE TO POSTURE | 12(8%) |
| HEART RATE RESPONSE TO DEEP BREATHING | 9(6%) |
| VALSALVA MANEUVER | 7(4%) |
| TOTAL | 41(26%) |

Abnormal Sympathetic Skin Response (SSR) - 38(25%)

Abnormal RR interval (ratio: < 1.2) - 45 (30%)

| ATROPHY | | UL | LL | BOTH |
|----------|--|----|----|------|
| DISTAL | | 35 | 27 | 28 |
| PROXIMAL | | 4 | 6 | 4 |
| WEAKNESS | | UL | LL | BOTH |
| DISTAL | | 41 | 33 | 31 |
| PROXIMAL | | 5 | 8 | 8 |

| REFLEX LOSS | | TOTAL |
|-----------------------|--|---------|
| GENERALIZED AREFLEXIA | | 9(6%) |
| ANKLE JERK LOSS | | 86(58%) |

| | MALE | FEMALE | TOTAL |
|--------------------------------------|---------|---------|---------|
| GLOVE AND STOCKING TYPE SENSORY LOSS | 36(39%) | 33(51%) | 69(44%) |
| POSITIVE ROMBERG TEST | 36(39%) | 33(51%) | 69(44%) |

| FASTING | MALE | FEMALE | TOTAL |
|-----------------|---------|---------|---------|
| 100 mg TO 150mg | 13(15%) | 10(17%) | 23(16%) |
| 150mg TO 200mg | 51(58%) | 37(61%) | 88(59%) |
| >200mg | 24(27%) | 13(22%) | 37(25%) |

| POSTPRANDIAL | MALE | FEMALE | TOTAL |
|----------------|---------|---------|---------|
| 150mg TO 200mg | 5(6%) | 7(11%) | 12(8%) |
| 200mg TO 250mg | 17(19%) | 13(22%) | 30(20%) |
| 250mg TO 300mg | 45(50%) | 29(48%) | 74(49%) |
| >300mg | 21(24%) | 11(19%) | 32(22%) |

| ECG | | |
|------------------|--|--------|
| ISCHEMIC CHANGES | | 13(8%) |
| ANTERIOR WALL MI | | 4(2%) |
| INFERIOR WALL MI | | 3(2%) |

Summary of NCS Study:

Distal Motor Latency

| | Total No. Of Patients | Normal | Increased | No response | Mean ± SD | Range |
|----------|-----------------------|--------|-----------|-------------|-----------|-----------|
| Median | 148 | 90 | 42 (4†) | 16 | 4.0 ± 1.8 | 3.1- 12.8 |
| Ulnar | 148 | 104 | 28 (2†) | 16 | 3.8 ± 1.0 | 2.6-9 |
| Tibial | 148 | 82 | 47 | 19 | 5.6 ± 1.5 | 3.6-13.7 |
| Peroneal | 148 | 84 | 44 | 20 | 5.5± 1.2 | 3.9-9.5 |
| Facial | 148 | 139 | 9 (5†) | - | | |

Distal Motor Amplitude

| | Total No. Of Patients | Normal | Decreased | No response | Mean ± SD | Range |
|----------|-----------------------|--------|-----------|-------------|-----------|----------|
| Median | 148 | 36 | 98 (32†) | 14 | 2.6 ± 1.8 | 0.2- 8.8 |
| Ulnar | 148 | 40 | 94 (30†) | 14 | 3.0 ± 2.1 | 0.5-9.1 |
| Tibial | 148 | 37 | 92 | 19 | 2.3 ± 1.5 | 0.3-6.5 |
| Peroneal | 148 | 35 | 93 | 20 | 1.8 ± 1.3 | 0.3-7.4 |
| Facial | 148 | 143 | 5 (1†) | - | | |

Motor Conduction Velocity

| | Total No. Of Patients | Normal | Decreased | No response | Mean ± SD | Range |
|----------|-----------------------|--------|-----------|-------------|------------|-----------|
| Median | 148 | 100 | 32 (3†) | 16 | 48.8 ± 7.1 | 19.0-59.0 |
| Ulnar | 148 | 104 | 28 (2†) | 16 | 48.3 ± 8.8 | 8.9-54.2 |
| Tibial | 148 | 90 | 39 | 19 | 38.4 ± 4.0 | 20.4-43.0 |
| Peroneal | 148 | 87 | 41 | 20 | 39.9 ± 2.1 | 23.0-42.0 |

F Waves Latency

| | Total No. Of Patients | Normal | Increased | No response | Mean ± SD | Range |
|--------|-----------------------|--------|-----------|-------------|------------|-----------|
| Median | 148 | 84 | 48 (10†) | 16 | 33.5 ± 3.9 | 25.0-75.0 |
| Ulnar | 148 | 94 | 38 (12†) | 16 | 33.8 ± 2.3 | 20-66 |

| | | | | | | |
|----------|-----|----|----|----|------------|------------|
| Tibial | 148 | 53 | 76 | 19 | 62.5 ± 4.5 | 34.0-45.2 |
| Peroneal | 148 | 64 | 38 | 46 | 63.2 ± 4.9 | 50.0-137.0 |

Sensory Amplitude

| | Total No. Of Patients | Normal | Decreased | No response | Mean ± SD | Range |
|------------|-----------------------|--------|-----------|-------------|------------|----------|
| Median | 148 | 71 | 62 (11†) | 4 | 12.0 ± 4.2 | 1.8-20.0 |
| Ulnar | 148 | 82 | 54 (8†) | 4 | 11.4 ± 3.1 | 1-15.0 |
| Lower Limb | 137 | 37 | 84 | 16 | 4.5 ± 2.6 | 1.3-15.7 |

Sensory Conduction Velocity (Sural)

| | Total No. Of Patients | Normal | Increased | No response | Mean ± SD | Range |
|------------|-----------------------|--------|-----------|-------------|------------|-----------|
| Lower Limb | 137 | 74 | 47 | 16 | 35.7 ± 4.4 | 26.0-49.0 |

† Patients with no upper limb symptoms

| Nerve | No. of nerves studied | No.(%) of patients with findings of focal demyelination | Conduction Conduction Block | Temporal Temporal Dispersion |
|----------|-----------------------|---|-----------------------------|------------------------------|
| Median | 148 | 46 | 5 | 2 |
| Ulnar | 148 | 32 | 3 | 1 |
| Peroneal | 148 | 46 | 3 | 21 |
| Tibial | 148 | 47 | 1 | 8 |

TYPES OF NEUROPATHIES

| | MALES | FEMALES | TOTAL |
|--------------------------------------|---------------------------|---------------------------|--------------------------------|
| SYMMETRIC SENSORIMOTOR | 37(25%) 24(†) 2(††) | 28(19%) 17(†) 4(††) | 65(44.0%) 41 (28%) 6(4%) |
| PAINFUL DISTAL SESORY | 24(16%) 22(†) | 19(13 %) 16(†) | 43(29%) 38(25.6%) |
| DIABETES WITH AIDP | 4(2.7%) | 1(0.3%) | 5(3%) |
| DIABETES WITH CIDP | 7(4.7%) | 1(0.3%) | 8(5%) |
| LUMBOSACRAL RALICULO PLEXONEUROPATHY | 9(6.1%) | 6(3.9%) | 15(10%) |
| MONONEURITIS MULTIPLEX | 4(2.7%) | 0 | 4(3%) |
| CRANIAL NEUROPATHIES | 5(3.37%) | 3(2.6%) | 8(6%) |

†WITH AUTONOMIC INVOLVEMENT

†† WITH CARPAL TUNNEL SYNDROME


VI. Discussion

DN is a common complication of DM and it is encountered in more than one third of diabetic patients⁽¹¹⁾. Pirar et al⁽¹²⁾ had found a five fold increase in the incidence of DN after 25 years of follow up. Although methods of assessing peripheralnerve function are improving, no single test is indicativeof nerve disease⁽¹⁰⁾ The San Antonio conference on diabeticneuropathy⁽⁹⁾ recommended obtaining ≥1 measurefrom each of the following categories to better define andclassify diabetic neuropathy: clinical symptoms, clinical examination, electrodiagnostic studies, quantitative sensorytesting and autonomic function testing. Likewise we in our study have used NCS as an extension of clinical examination.

Discordance between nerve conduction velocity and symptoms and signs of DN has been reported before^(13,14) We found that 36% of our patients with symptomatic DN had normal NCS, which is higher than that reported by Sangiorgio et al⁽¹³⁾ and Fedele et al⁽¹⁴⁾. Also nearly 30% of patients who did not have symptoms related to upper limbs showed some abnormality in NCS. This discordance between symptoms and NCS means that we can not rely on patient's symptoms for the diagnosis of DN and we need NCS for better assessment and diagnosis of DN.

The various clinical types ofPN in this study correlate well with most studies all overthe world, with sensorimotor polyneuropathy—diagnosedin 48%—being the most common⁽¹⁵⁾

e 1. Various clinical types of peripheral neuropathy



Symptoms of PN manifested at a significantly lower age in our study. This is in agreement with Vondrova and coworkers in Czech, who found that diabetic polyneuropathy manifested at a younger age⁽¹⁶⁾ The average age of onset was 40 years in males and 42.3 in females.

There were no significant relation between Diabetic neuropathy and sex, BMI, hypertension or hyperlipidemia which is in agreement with the findings of Hillson et al and Maser et al

The relation between smoking and DN is conflicting, some reports showed significant relation⁽¹⁵⁾ while others⁽¹⁶⁾ didn't find any relation. We found no significant relation between Diabetic neuropathy and smoking.

The overall high frequency of diabetic AN in this study (54%) was in keeping with what has been seen by other workers. Fernandez-Castaner and colleagues⁽¹⁷⁾ had reported that 53% of an unselected series of diabetics had symptoms suggestive of autonomic dysfunction, while Thiand coworkers⁽¹⁷⁾ documented that 67.6% of Vietnamese diabetics have cardiac AN. Most studies suggest a fairly close association between AN and sensory neuropathy. This was again true in our case, where all diabetics with AN had an associated somatic neuropathy that precedes abnormalities of autonomic function⁽¹⁸⁾.

While no significant relation has been found between age and abnormal NCS, a strong relation was found with poor glycemic control, this means that even young patients can develop alteration in NCS if they are not well controlled. As the pathogenic mechanisms of Diabetic neuropathy are not fully understood, there is no satisfactory and fundamental therapy for Diabetic neuropathy. Therefore, further researches are needed especially into pathogenic mechanisms in order that satisfactory treatment is achieved. Good glycemic control is essential if the risk of diabetic complications is to be minimized.

There was a strong relation between baseline glycated hemoglobin and the loss of tactile sensation and temperature sensation. Intensive diabetic control had been shown to reduce the occurrence of clinical neuropathy by 60%. Several prospective randomized clinical trials have shown the beneficial effect of tight glycemic control on the progression of chronic microvascular complications of DM. This means that strenuous control of blood glucose is the key in the ultimate prevention of diabetic neuropathy.

In our study too prolonged and poorly controlled DM were the most significant factors associated with Diabetic neuropathy as has been reported by others^(13,14,15,16). A significant proportion of patients in our study who were on insulin had severe PN. This relationship may have more to do with poor control of diabetes in these patient, rather than insulin usage by itself. Similar to our report Cheng et al⁽¹⁷⁾ had also shown a significant relation between insulin use and Diabetic neuropathy.

Cranial neuropathies are known to occur commonly in diabetics. There are only few studies on the frequency of clinically apparent cranial nerve lesions associated with diabetes mellitus. Large retrospective series revealed 0.97% incidence of oculomotor and facial nerve palsies in diabetic patients over a 25-year period which was 7.5 fold more frequent than in the non diabetic control group (Urban et al., 1999). Urban et al. (1999) reported that 77.5% of their diabetic patients demonstrate significant prolongation of distal motor latency of VIIth nerve. Johnson and Waylonis (1964) stressed the fact that, even though the conduction of limb nerves were unaffected, subclinical involvement of the facial nerve was present in a group of known diabetics (Johnson et al., 1964; Waylonis et al., 1964). In our study a total of 8(5%) patients had clinical evidence of cranial nerve involvement, among which 6 patients had facial nerve involvement, 2 patients had painful oculomotor palsy. But on nerve conduction studies 14(9%) patients had abnormality in the form of prolonged DML (9 patients)

and axonal changes (5 patients). Although a few asymptomatic patients in our study did show some NC abnormalities, this was not statistically significant. This may be due to the fact that most of the polyneuropathy in diabetes being length-related, facial nerve conduction may be less impaired than limb nerve conduction.

Several workers have demonstrated subclinical involvement of nerve fibres in patients with diabetes by comparing conduction between patients and normal subjects. These studies concerned patients with or without diabetic neuropathy (Lawrence and Locke, 1961; Mulder et al., 1961; Skillman et al., 1961; Fagerberget al., 1963; Mayer, 1963; Gamstorp, 1964; Eeg-Olofsson and Petersen, 1966) and mixed groups (Gregersen, 1964, 1967). In the individual patient, slowing in motor conduction was often borderline in the non-affected nerves of patients with isolated peripheral nerve lesions (Gilliatt and Willison, 1962).

In our study, although we did not include asymptomatic diabetics, we were able to analyze the conduction in clinically unaffected limb (mostly upper limb). Out of 56 patients who did not have upper limb symptoms 32 patients showed abnormalities in motor conduction while 15 patients had additional sensory disturbance.

Many patients with sensory motor neuropathy (76 patients) showed a prolongation in distal motor latency in addition to more than 50% reduction in amplitude, this we assume to be due to the loss of myelinated fibres. Also 5 patients with sensory motor neuropathy, in addition to prolongation in latency and reduction in amplitude, showed a significant slowing in conduction velocity pointing to the possibility of additional focal abnormalities.

The slowing in the common peroneal nerve was the electrophysiological parameter most closely related to the severity of the neuropathy ($P < 0.001$). In previous studies, the average slowing in motor conduction along the median and ulnar nerves has been reported to be as severe as in the common peroneal nerve, both in patients with and without clinical signs of neuropathy (Mulder et al., 1961; Lawrence and Locke, 1962; Mayer, 1963; Gamstorp, 1964; Gregersen, 1967).

In our patients, distal slowing as measured by DML was as pronounced in the upper as in the lower extremities, but in the more proximal segments of the nerves (as measured by F wave latency) slowing was 1.5 times greater in the lower limb nerves than in the upper. This is consistent with the findings of Skillman et al. (1961) and of Johnson (1962) and with the more pronounced clinical involvement of the legs than of the arms.

The 2 main pathophysiological mechanisms proposed for diabetic neuropathy are nerve ischemia (microangiopathy) and metabolic derangement of nerves. However, DM is one of the group of autoimmune disorders, and there is growing evidence that immune and inflammatory processes play a role in some of the neuropathies occurring in DM, including demyelinating polyneuropathy. Mitchell et al 7 reported finding major histocompatibility class II antigen expression on Schwann cells, similar to that found in I-CIDP, in the nerves of patients with diabetic amyotrophy. Younger et al 8 found that upto 60% of sural nerve biopsy specimens from 20 diabetic patients with various types of neuropathy had lymphocytic microvasculitis or perivasculitis, and endoneurial T-cell infiltrates, with increased expression of tumor necrosis factor α cytokines, and components of the membrane attack complex. Several studies have suggested that autoantibodies directed against phospholipid, gangliosides, sulphatide, nerve growth factor, and advanced glycation end products may play a role in the pathogenesis of diabetic neuropathy. This probably explains the large number of patients in our study showing focal changes in NCS.

LIMITATION OF OUR STUDY:

1. Potential bias of patient referral. Most of the patients referred to our OPD had a severe neuropathy
2. Lack of biopsy correlation.

VII. Conclusions

1. Among the different types of Diabetic neuropathy, chronic sensorimotor neuropathy was the commonest, with a prevalence of 44%. Autonomic neuropathy (AN) had a prevalence of 28%. AN was almost always associated with sensory neuropathy. Among the focal neuropathies CIDP was the commonest
2. 65% of patients with clinical neuropathy showed abnormalities on nerve conduction studies. Nearly 30% of patients with no upper limb symptoms showed abnormalities in NCS. Showing a discordance between symptoms and nerve conduction studies.
3. Longer duration of DM strongly correlated to abnormalities in NCS, the mean duration of DM in patients with both upper and lower limb NCS abnormalities was 7.4 years as compared to 3.1 years in those with only lower limb changes. It merely reflect the increased probability of finding more severe manifestations of a neuropathy when the diabetes has lasted longer.
4. There was no relation between abnormal NCS and patients age, sex, type of Diabetes mellitus, hypertension, hyperlipidemia or smoking.
5. Prolonged poorly controlled diabetes was an important risk factors associated with diabetic neuropathy. Aggressive/strict control of blood glucose is the key in the ultimate prevention of diabetic neuropathy

6. Lowerlimb F wave latency prolongation may correlate well with severity of the neuropathy.
7. Presence of focal abnormalities in nerve conduction in addition to diffuse changes indicates that immune mediated mechanisms may play an additional role in development of diabetic neuropathy.

References

- [1]. Marchal de Calvi. J: (1884) Recherches sur les Accidents Diabetiques. Paris Cited by Jordon 1936.
- [2]. Bouchard M. (1887) Loss of the knee-phenomenon in diabetes Brit Med. J. p 237.
- [3]. Althaus J. (1885) On sclerosis of the spinal cord. London Longman S.
- [4]. WHO expert committee on diabetes mellitus, Second report, WHO Tech Rep Ser 646
- [5]. World Health Organisation 1980, Geneva, p 1-80.5. Pavy F.W. (1904) On diabetic neuritis, Lancet, 2: 17.
- [6]. Bruns L. (1890) Uber neuritische Lahmungen beim diabetes Mellitus. Bert Klein. Wochenschr. 27: 509.
- [7]. Charcot M. (1890) Sur un cas de paraplegicdiabetique arch. Neurol. (Paris) 19: 318.
- [8]. Ogle J.W. (1866) On disease of the brain as a result of diabetes mellitus. St George's Hospital. Rep. 1: 157.
- [9]. Leyden E. (1893) Beitrag Zur Klinik des Diabetes mellitus Wien. Med. Wochenschr. 43.926.
- [10]. Pryce T.D. (1893) On Diabetes neuritis with a Clinical and Pathological description of three cases of diabetic pseudo tabes Brain 16: 416.
- [11]. ALBERT LAMONTAGNE Electrophysiological studies in diabetic neuropathy J. Neurol. Neurosurg. Psychiat., 1970, 33, 442-452
- [12]. Felig P, Bergman M. The endocrine pancreas: diabetes mellitus. In: Felig P, Baxter J, Freshman LA, eds. Endocrinology and Metabolism. 3rd ed. New York, NY: McGraw-Hill Co; 1995:1107-1205
- [13]. DeBlock CE. Diabetes mellitus type I and associated organ-specific autoimmunity. Verh K AcadGeneesk Belg. 2000;62:285-328.
- [14]. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral Neuropathy. 3rded. Philadelphia, Pa: WB Saunders Co; 1993:1219-1250.
- [15]. Brown FM, Brink SJ, Freeman R, Rabinowe SL. Anti-sympathetic nervous system autoantibodies: diminished catecholamines with orthostasis. Diabetes. 1989;38:938-941.
- [16]. Shigeta H, Yamaguchi M, Nakano K, et al. Serum auto-antibodies against sulphatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care. 1997;20:1896-1899.
- [17]. Mclivevic Z, Newlon P, Pittenger G, Stanberry K, Vinik A. Anti-ganglioside GM1antibody and distal symmetric “diabetic polyneuropathy” with dominant motor features. Diabetologia. 1997;40:1364-1365
- [18]. Rundles, R.W. (1945) Diabetic neuropathy: general review with report of 125 cases. Medicine (Baltimore) 24: 111.

Neeraj.E. “ Study of Incidence, Clinical Profile and Electrophysiological Patterns in Each Type of Diabetic Neuropathy and the Extent of Their Clinical Correlation.” IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol. 18, no. 5, 2019, pp 67-75.